BioCentury | Mar 13, 2021
Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

...$16.65 after the San Diego-based company raised $80 million in its IPO. Longboard spun out of Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...trials for acute respiratory failure (ARDS) and pneumonia in COVID-19 patients. Gunjan Ohri Prometheus Biosciences Inc. Longboard Pharmaceuticals Inc. Arena Pharmaceuticals Inc. Monte...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...II trials are being discontinued. Arena evaluating options for olorinab after Phase II missArena Pharmaceuticals Inc. (NASDAQ:ARNA...
...and Co. Kronos Bio Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus BioSciences Inc. Pfizer United Therapeutics Corp. Sumitomo Dainippon Pharma Co. Ltd. Arena Pharmaceuticals Inc. Azura...
BioCentury | Feb 17, 2021
Management Tracks

Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers

...recently CMO and head of development at Santhera Pharmaceuticals Holding AG (SIX:SANN).Autoimmune and hypertension play Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...and CSO at two stem cell startups. BC Staff Athersys Inc. Strongbridge Biopharma plc Freeline Therapeutics Holdings plc AlzeCure Pharma AB Arena Pharmaceuticals Inc. Prime...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...Culley will serve as interim CFO until the position is filled. Longboard spun out of Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...with FibroGen as an executive adviser to the CEO through March 15, 2021. Paul Streck joined Arena Pharmaceuticals Inc. (NASDAQ:ARNA) as...
...a venture partner. Stack was general manager of new business creation at GE Ventures. Danielle Golovin FibroGen Inc. Arena Pharmaceuticals Inc. Frequency...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

...endpoint support moving into Phase III testing.Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...EDG1) – Sphingosine 1-phosphate receptor 1 Stephen Hansen etrasimod (APD334) Arena Pharmaceuticals Inc. atopic...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

...road map includes a potential IPO.The long-planned process of externalizing Longboard Pharmaceuticals Inc. from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...Therapeutics for neurological indicationsOrigin of technology: Biopharma spinoutDisease focus: NeurologyClinical status: ClinicalFounded: 2020University collaborators: NoneCorporate partners: Arena Pharmaceuticals...
...its disclosed compoundsTARGETSCB2 (CNR2) - Cannabinoid receptor 2S1PR1 (S1P1; EDG1) - Sphingosine 1-phosphate receptor 1 Paul Bonanos Arena Pharmaceuticals Inc. Longboard...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...partners Cytokinetics and Amgen and ADP418 from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...UC, while S1PR1 agonist etrasimod from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...S1PR1 agonist etrasimod for ulcerative colitis, the rights to which Everest has obtained from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
Items per page:
1 - 10 of 636
BioCentury | Mar 13, 2021
Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

...$16.65 after the San Diego-based company raised $80 million in its IPO. Longboard spun out of Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...trials for acute respiratory failure (ARDS) and pneumonia in COVID-19 patients. Gunjan Ohri Prometheus Biosciences Inc. Longboard Pharmaceuticals Inc. Arena Pharmaceuticals Inc. Monte...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...II trials are being discontinued. Arena evaluating options for olorinab after Phase II missArena Pharmaceuticals Inc. (NASDAQ:ARNA...
...and Co. Kronos Bio Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus BioSciences Inc. Pfizer United Therapeutics Corp. Sumitomo Dainippon Pharma Co. Ltd. Arena Pharmaceuticals Inc. Azura...
BioCentury | Feb 17, 2021
Management Tracks

Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers

...recently CMO and head of development at Santhera Pharmaceuticals Holding AG (SIX:SANN).Autoimmune and hypertension play Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...and CSO at two stem cell startups. BC Staff Athersys Inc. Strongbridge Biopharma plc Freeline Therapeutics Holdings plc AlzeCure Pharma AB Arena Pharmaceuticals Inc. Prime...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...Culley will serve as interim CFO until the position is filled. Longboard spun out of Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...with FibroGen as an executive adviser to the CEO through March 15, 2021. Paul Streck joined Arena Pharmaceuticals Inc. (NASDAQ:ARNA) as...
...a venture partner. Stack was general manager of new business creation at GE Ventures. Danielle Golovin FibroGen Inc. Arena Pharmaceuticals Inc. Frequency...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

...endpoint support moving into Phase III testing.Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...EDG1) – Sphingosine 1-phosphate receptor 1 Stephen Hansen etrasimod (APD334) Arena Pharmaceuticals Inc. atopic...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

...road map includes a potential IPO.The long-planned process of externalizing Longboard Pharmaceuticals Inc. from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
...Therapeutics for neurological indicationsOrigin of technology: Biopharma spinoutDisease focus: NeurologyClinical status: ClinicalFounded: 2020University collaborators: NoneCorporate partners: Arena Pharmaceuticals...
...its disclosed compoundsTARGETSCB2 (CNR2) - Cannabinoid receptor 2S1PR1 (S1P1; EDG1) - Sphingosine 1-phosphate receptor 1 Paul Bonanos Arena Pharmaceuticals Inc. Longboard...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...partners Cytokinetics and Amgen and ADP418 from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...UC, while S1PR1 agonist etrasimod from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...S1PR1 agonist etrasimod for ulcerative colitis, the rights to which Everest has obtained from Arena Pharmaceuticals Inc. (NASDAQ:ARNA...
Items per page:
1 - 10 of 636